Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major ...

What keeps some immune systems youthful and effective in warding off age-related diseases? In new research done on mice, scientists point the finger at a small subset of blood stem cells, which make ...

A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...

The promise of a one-and-done CRISPR in­fu­sion is be­gin­ning to look more re­al than ever. On Thurs­day, In­tel­lia ...

Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...

Contributing Writer for The Prospect Lily Hutcheson reflects on her fall break in London for a freshman seminar.

When the scientists used CRISPR to edit out these genes, blood stem cells reversed their natural tendency and produced more innate immune cells instead of adaptive immune cells-;like in the early ...

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

Charting the "dark matter" of the viral universe has implications not just for biotechnology—but potentially for battling the ...